Heron Therapeutics, INC /DE/ DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Heron Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, with key proposals including director elections and equity plan amendments.
NASDAQ
Heron Therapeutics is seeking shareholder approval for the potential issuance of common stock exceeding 19.99% of current outstanding shares, stemming from the conversion of convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
NASDAQ
DEFA14A: Heron Therapeutics Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
Heron Therapeutics has scheduled its annual stockholder meeting for June 12, 2025, and is seeking votes on director elections, auditor ratification, executive compensation, and the frequency of executive compensation votes.
NASDAQ
Heron Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring proposals for director elections, auditor ratification, and executive compensation.
NASDAQ
Heron Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 13, 2024, to vote on several proposals, including the election of directors, ratification of the accounting firm, executive compensation, and amendments to the company's certificate of incorporation and equity incentive plans.